Guidance for Organizations performing in vivo Bioequivalence Note: ANVISA is constantly redesigning its website starting in Aug Anvisa-Guidance-for-Pharmaceutical-Equivalence-and-Bioequivalence-of-Nasal -Sprays-and-Aerosols_生物学_自然科学_专业资料。Agência. Since , ANVISA has been publishing several Resolutions to establish criteria and requirements to conduct a bioequivalence Trial to register drugs that have.

Author: Mikora Nejinn
Country: Iceland
Language: English (Spanish)
Genre: Travel
Published (Last): 16 March 2008
Pages: 96
PDF File Size: 17.14 Mb
ePub File Size: 5.18 Mb
ISBN: 276-7-77395-202-7
Downloads: 46835
Price: Free* [*Free Regsitration Required]
Uploader: Kazranris

Published online Feb 4. Another exclusion criteria used for nasal sprays and aerosols is the occurrence of a sneeze two hours after administration of the drug.

Global Bioequivalence / Bioavailability Regulatory Guidance Documents §¯`·.¸¸.·´¯`·.¸¸.

Current Regulatory Agenda of ANVISA, which contains possible future resolutions to be revised over —, includes a discussion on biowaiver requirements and on possible in vitro and in vivo comparability tests for these products [ 5 ]. Parenteral aqueous solutions do not have to be formulated with the same inactive ingredients as their reference formulations.

Other regulatory guidances that should be followed for the establishment of BE are the following: Test must be conducted in unities that have been primed in accordance with the instructions of use.

However, in the case of parenteral oily solutions, the type of oil used as a vehicle has to be qualitatively the same. Sponsors, Contract Research Organizations and Monitors: Mechanical actuation proceedings must booequivalence controls that are adequate for critical parameters such as actuation strength, speed, and time interval between actuations.

Analysis of the Charge and Recharging data: Pharmacodynamic Studies for Nasal Sprays and Bioequivalemce. Volunteers must be previously trained to use the apparatus that will receive the formulation to inhale properly; Before nasal administration 1 minutevolunteers must blow their noses; During nasal application, one fkr the nostrils must be obstructed while administration is executed in the other nostril.

Volunteers, in order to be included in these studies, must be submitted in a clinical evaluation, and no bioeauivalence disease must be found, which includes allergic rhinitis, nasal septal debytion, and adenoid, as they might alter deposition of drug into nasal mucous.



Because the legal framework of the Brazilian Health Surveillance Agency ANVISA is available only in Portuguese, it might have been difficult to search information properly or to identify updated guidelines. Brazilian Health Surveillance Agency. Presentation of Biopharmaceutical and Bioanalytical Data in Module 2. GL for the Monitoring of Clinical Investigations: Spray Pattern can be characterized and quantified by manual or automatic image, as long as validated.

Food and Drug Administration: Accessed 5 Nov Inflammation of a CRO in order to comply with written instructions rather than following common sense. Concerning the formulation composition for biowaiver of oral dosage forms, the test drug product should preferably use the same excipients as the reference drug product, but other excipients that are well established for the dosage form, administration route, and drug substance in usual amounts are allowed 4.

For that reason, stability of statistical procedures in general must be studied and specifically estimation techniques in presence of deviations from hypothesis which they are based and use techniques that are not very sensitive to these deviations. Gelfusoand Tais Gratieri. SinceANVISA has been publishing several Resolutions to establish criteria and requirements to conduct a bioequivalence Trial to register drugs that have been updated along the development of science.

Disclaimer Although this Collection contains information of a legal nature, it has been developed for informational purposes only and does not constitute legal advice or opinions as to bioequivalejce current operative laws, regulations, or guidelines of any jurisdiction. This article has been cited by other articles in PMC.

Copies available at our site are denoted by this icon: GL on multiplicity issues in clinical trials: Good clinical practice GCP: In case of any other authorized Pharmacopoeia be used, the requirements of monograph vuidelines be complemented with the essays that are described in General Methods of current Brazilian Pharmacopoeia, described for the pharmaceutical form studied.


There must be an application of placebo with the same apparatus to evaluate fog of volunteer to receipt of drug without reactions, which, generally, result in sneezing. Linear association measured between two variables.

Journal of Bioequivalence & Bioavailability

Bioequivalenc of GC Equipment: Provides information about pharmaceutical equivalence determination and dissolution profile comparison. The first rectification would be the guideline cited in Table I presented by Davit and co-workers 1. Please review our privacy policy.

Each guixelines must receive drug by an individual flask; All volunteers and staff must wear clean area clothing, including caps, masks, and gloves; Before each application, the device must be tested by trained staff and execution of about 5 actuations is recommended, outside the building, on the day prior to the testing day; Flasks must be weighted after 5 actuations and, again, after administration in the volunteers.

Inform that the Resolution proposal shall be availed, in its totality, during the consultation period at the address http: Thus, results of the following tests must be submitted: Pharmacodynamic bioequivalencw must comply with bioeuqivalence following criteria: The EMA redesigned its website in and We would like to comment on an interesting review article on the similarities and differences among international guidelines for determining bioequivalence BE of generic drug products 1.

Actually, bioequivalence studies with pharmacodynamic endpoints are not required for any topical dosage form. Received Nov 20; Accepted Jan Formulations used for Systemic Effects: